Drs McDade and Cohen discuss ATN (amyloid, tau, neurodegeneration) classification and its use in clinical practice to manage Alzheimer’s disease.
Videos
The neurosurgeon at Allegheny Health Network provided background on a new, state-of-the-art tool designed to ultimately improve neurosurgical procedures. [WATCH TIME: 3 minutes]
The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]
The scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai, spoke about a talk given at the 2022 AES conference on seizures after ischemic. [WATCH TIME: 5 minutes]
The director of the Montefiore Einstein Center for the Aging Brain provided insight on how the 5-Cog assessment tool is specifically tailored for people from a range of racial and ethnic background, education levels, and socioeconomic circumstances. [WATCH TIME: 4 minutes]
The assistant professor in the Department of Neurology at the University of Wisconsin spoke about the differences between health disparities and health equity in epilepsy care at the 2022 AES Conference. [WATCH TIME: 3 minutes]
The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on how lecanemab’s FDA approval changes the capabilities of treating Alzheimer disease in its earliest stages. [WATCH TIME: 3 minutes]
The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center spoke about his experience in a debate on surgery in genetic disorders at the 2022 AES Conference. [WATCH TIME: 3 minutes]
The Baldwin Keyes professor of neurology at Thomas Jefferson University, spoke with us at the 2022 AES Conference about the definition of a seizure. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending January 7, 2022. [WATCH TIME: 4 minutes]
The executive vice president of Global Head of Research and Development at Jazz Pharmaceuticals, spoke on the results from the BECOME study presented at the 2022 AES Conference. [WATCH TIME: 6 minutes]
Dr Cohen emphasizes the importance of engagement of primary care physicians in identification of Alzheimer’s disease symptoms and pathology.
Dr. Atri discusses his approach to diagnosis and Dr. McDade updates on the use of tau-PET for diagnosis of Alzheimer’s disease.
The professor of neurology at the University of Toronto talked about 3 conditions that were discussed during the epilepsy therapies symposium at the 2022 AES Conference. [WATCH TIME: 5 minutes]
The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease, and the new ways to approach prevention. [WATCH TIME: 4 minutes]
The professor of neurology at the University of Toronto spoke at the 2022 AES Conference about genetic approaches to comorbidities for patients with epilepsy. [WATCH TIME: 5 minutes]
The director of research at the TSC Alliance spoke with us at the 2022 AES Conference about future research to be conducted on patients with TSC such as the PREVeNT trial. [WATCH TIME: 6 minutes]
The professor of clinical geriatric epidemiology at Karolinska Institutet discussed a subgroup analysis of the FINGERS trial and the clinical utility of the precursor to serum brain-derived neurotrophic factor. [WATCH TIME: 3 minutes]
The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided perspective on the reasons to not solely rely on anti-amyloid treatments to treat Alzheimer disease. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending December 31, 2022. [WATCH TIME: 3 minutes]
Dr Atri shares his excitement about ongoing research and the use of biomarkers and imaging for management Alzheimer’s disease.
Drs McDade and Sabbagh discuss heterogeneity in Alzheimer’s disease and structural polymorphism and genetic mosaicism seen in patients.
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
A panel of experts discuss COVID-19 vaccine efficacy for patients undergoing treatment for multiple sclerosis.
At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about sleep testing for patients with epilepsy. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending December 24, 2022. [WATCH TIME: 4 minutes]
The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the neurodevelopmental impacts delaying seizures could lead to in tuberous sclerosis complex. [WATCH TIME: 2 minutes]
The associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital spoke about sleep disorders and epilepsy in adults at the 2022 AES annual meeting. [WATCH TIME: 5 minutes]
Drs Atri and Cohen discuss biomarkers for Alzheimer’s disease and the challenges in their use in routine practice.
Four Alzheimer’s disease expert discuss our current understanding of Alzheimer’s disease pathology and the presence of amyloid and tau pathologies in patients.
Advertisement
Advertisement
